Literature DB >> 30900952

Disease-modifying therapies should be stopped in NMOSD patients in remission - Yes.

Eslam Shosha1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30900952     DOI： 10.1177/1352458519829694

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  3 in total

1.  Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.

Authors:  Saharat Aungsumart; Metha Apiwattanakul
Journal:  PLoS One       Date:  2020-02-12       Impact factor: 3.240

2.  Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies.

Authors:  Su-Hyun Kim; Hyunmin Jang; Na Young Park; Yeseul Kim; So-Yeon Kim; Min Young Lee; Jae-Won Hyun; Ho Jin Kim
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-02-23

3.  Results of a Survey on Diagnostic Procedures and Treatment Choices for Neuromyelitis Optica Spectrum Disorder in Korea: Beyond the Context of Current Clinical Guidelines.

Authors:  Hye Lim Lee; Su-Hyun Kim; Jin Myoung Seok; Byung Jo Kim; Ho Jin Kim; Byoung Joon Kim
Journal:  J Clin Neurol       Date:  2022-03       Impact factor: 3.077
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.